IMGN Financial Facts

Clinical materials reimbursement: 46K
Total revenues: 7.66M
See Full Income Statement

Deferred revenue, net of current portion: 19.16M
Current portion of deferred revenue: 13.63M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate +73.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +51.9% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/12/24 Q423 N/A$0.13 N/A N/A$129.48M N/A N/A N/A
2/9/24 Q423 N/A$0.13 N/A N/A$129.48M N/A N/A N/A
11/2/23 Q323 $0.10$0.04 +$0.06$113.4M$103.68M N/A Details
7/31/23 Q223 -$0.02-$0.13 +$0.11$77.4M$49.15M N/A Details
4/28/23 Q123 -$0.16-$0.25 +$0.09$49.9M$20.97M N/A Details
3/1/23 Q422 -$0.23-$0.30 +$0.07$41.17M$17.43M N/A Details
2/13/23 Q422 N/A-$0.30 N/A N/A$17.43M = N/A N/A
2/10/23 Q422 N/A-$0.30 N/A N/A$17.43M = N/A N/A